Ian Walker
Neurology · Cherry Hill, NJNPI 1609261726
Payments from drug & device makers
Across 139 payments — averaging $73.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- AbbVie$2K
- Boston Scientific$2K
- Medtronic$1K
- Acadia Pharmaceuticals Inc$191
- UCB, Inc.$158
- plus $672 from 17 others
What the payments were for
- Consulting fees$1,75017%
- Travel & lodging$5,44553%
- Food & beverage$2,94729%
- Education$1211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $4,445 |
| AbbVie | 27 | $2,118 |
| Boston Scientific | 7 | $1,595 |
| Medtronic(2 entities) | 14 | $1,084 |
| Acadia Pharmaceuticals Inc | 21 | $191 |
| UCB, Inc. | 12 | $158 |
| Neurocrine Biosciences, Inc. | 8 | $157 |
| MDD US Operations, LLC | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| SK Life Science, Inc. | 3 | $65 |
| Biogen | 2 | $41 |
| Lundbeck LLC | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Pfizer | 1 | $21 |
| CSL Behring | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$4,073
- VERCISE$1,301
- ACTIVA$445
- GENERAL DBS$125
How this compares
$10,263 in reported general payments places this provider in the 70th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $206,292 |
| NuplazidPimavanserin Tartrate | 11 | $94,840 |
| Tetrabenazine | 18 | $90,821 |
| NourianzIstradefylline | 33 | $63,344 |
| GocovriAmantadine Hcl | 17 | $45,310 |
| RytaryCarbidopa/Levodopa | 33 | $33,221 |
| NeuproRotigotine | 20 | $32,245 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 697 | $22,683 |
| Rasagiline Mesylate | 66 | $10,342 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 142 | $5,946 |
| Primidone | 183 | $5,391 |
| Propranolol Hcl | 150 | $3,418 |
| AmantadineAmantadine Hcl | 51 | $2,706 |
| Modafinil | 17 | $2,513 |
| Propranolol Hcl ErPropranolol Hcl | 37 | $1,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $157 | $206,29223 claims |
| Acadia Pharmaceuticals IncNuplazid | $191 | $94,84011 claims |
| Kyowa Kirin, Inc.Nourianz | $15 | $63,34433 claims |
| MDD US Operations, LLCGocovri | $106 | $45,31017 claims |
| Amneal Pharmaceuticals LLCRytary | $33 | $33,22133 claims |
| UCB, Inc.Neupro | $158 | $32,24520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 521 neurology providers in New Jersey.
Other neurology in Cherry Hill
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
- Machteld HillenNewark$999K
- Matthew TremblayLivingston$812K
- Noah GilsonWest Long Branch$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.